Không có sản phẩm nào trong giỏ hàng của bạn
[PharmApp] - Các phần mềm và nền tảng dùng trong nghiên cứu phát triển công thức thuốc và nghiên cứu lâm sàng
12/08/2022
Admin
[tintuc]
Some significant developments of 1960s
Interesting development |
Application |
Developer/team/ organization |
Year |
Ref. |
FORTRAN IV |
First programming language mainly
used for numeric
and scientific computations |
IBM |
1962 (FORTRAN IV) |
[12] |
Simula |
Simulation programming language |
Kristen Nygaard at Norwegian
Computing Center, Oslo |
1962 |
[18] |
SNOBOL |
Programming language—string- oriented and symbolic language |
David J. Farber, Ralph E. Griswold, and Ivan P. Polonsky, AT&T Bell Laboratories |
1962 |
[19] |
Quantum Chemistry Program Exchange (QCPE) |
Repository of programs and softwares for
sharing codes |
Prof. Shull and colleagues from Air Force Office
of Aerospace Research (ARAC), Indiana University |
1963 |
[21] |
FORMAC |
The first computer algebra system |
Jean E. Simmet from IBM |
1964 |
[17] |
QSAR Modelling |
Method for determination of biological activity by correlating it with chemical
structure of compound |
Corwin Hansch and Toshio
Fujita |
1964 |
[24] |
Mathematical equations |
Developed methods to mathematically report the toxicity
profile of chemicals |
Spencer M. Free and James W. Wilson |
1964 |
[25] |
BMDP |
Software used for Statistical data analysis |
Wilfrid Dixon from University of California |
1965 |
[26] |
SAMCEF |
Software used
for finite- element
analysis |
SAMTECH |
1965 |
[27] |
ORTEP |
Software used for crystal
structure illustrations |
Oak Ridge National Laboratory (ORNL) |
1965 |
[28] |
CSMP III |
Software used for Solving
and modeling of differential equations |
IBM |
1967 |
[29] |
SPSS |
Software used for statistical data analysis |
University of Stanford (Norman
H. Nie, C. Hadlai (Tex) Hull,
and Dale H. Bent) |
1968 |
[20] |
Mouse |
For pointing and for improving speed
and accuracy of computers |
Douglas Engelbart |
1968 |
[14] |
RKS 100-86 (Rollkugel- Steuerung) |
First rolling
ball mouse |
Rainer Mallebrein of Telefunken, Germany |
1968 |
[16] |
Some significant developments of 1970s
Interesting development |
Application |
Developer/team/ organization |
Year |
Ref. |
Gaussian |
Software used for computational
chemistry |
Prof. John A Pople’s from Carnegie Mellon University |
1970 |
[35] |
ARPANET’s Netword e-mail System; First electronic mail program |
Wide-area packet- switching network |
Ray Tomilson at Advanced
Research Projects Agency (ARPA) |
1971 |
[52] |
Protein Data Bank (PDB) |
Database of protein structures |
Walter Hamilton at Brookhaven National Laboratory |
1971 |
[39] |
UNIX |
Computer operating system |
Ken Thompson, Dennis Ritchie,
Brian Kernighan, Douglas McIlroy, and Joe Ossanna at Bell Labs |
1971 |
[53] |
Floppy disk |
Used for data storage |
IBM |
1972 |
[31] |
SQL |
Structured Query Language used in data analysis |
IBM |
1972 |
[54] |
Minitab |
Statistical software |
Minitab LLC |
1972 |
[42] |
XTL |
Software used for crystallographic study |
Syntex |
1974 |
[45] |
Version 6 Unix |
First version of Unix operating system |
AT&T Bell Laboratories |
1975 |
[55] |
CLU |
Programming language |
Massachusetts Institute of Technology |
1975 |
[56] |
BS2000 |
Mainframe computer operating system |
Siemens AG and later
by Fujitsu Technology Solutions |
1975 |
[30, 57] |
MAtrix LABoratory (MALTAB) |
Educational Software package for calculations related to matrices |
Cleve Moler |
1976 |
[33] |
MMI/MMPI |
Software launched on QCEP platform for making chemical structures with increased accuracy |
N L Allinger from University of Georgia |
1976 |
[21] |
SAS |
Software for statistical data analysis |
North Carolina State University and SAS Institute |
1976 |
[33] |
VAX11/780 |
Minicomputer with
low cost and extendable storage |
Digital Equipment Corporation (DEC) |
1977 |
[12] |
Apple II |
Personal computers with floppy drive
so that the user can store softwares |
Developed by Apple Inc. |
1977 |
[58] |
Interesting development |
Application |
Developer/team/ organization |
Year |
Ref. |
General Atomic and Molecular Electronic Structure System
(GAMESS) |
Software for computational chemistry |
Iowa state
University |
1977 |
[43] |
Quantitative Drug Design: A Critical Introduction |
A book on drug design |
Yvonne Connolly Martin |
1978 |
[49] |
GROningen MOlecular Simulation (GROMOS) |
Software used for field force for molecular dynamics
simulation |
University of Groningen |
1978 |
[44] |
Word star |
Word processing application for microcomputers |
Rob Barnaby |
1978 |
[59] |
VisiCalc |
Software used as data entry |
Bob Frankston |
1979 |
[60] |
PharmApp for developments of 1980s
Interesting development |
Application |
Developer/team/ organization |
Year |
Ref. |
SYBYL |
Software for molecular modeling,
homolog recognition, structure, and function prediction |
Tripos (now Certara from 2008) |
Early 1980s |
[87, 88] |
Super Calc |
Software used as advanced
calculator app, which is used
available on smartphones and tablets |
Sorcim |
1980 |
[83] |
VAX-11/780; |
Minicomputers, 8000 |
Digital Equipment |
1977– |
[6, 89, |
VAX 8000
series |
series, offered higher |
Corporation |
1989 |
90] |
performance than
that of |
||||
VAX-11/780 |
||||
MATLAB |
Software used for matrix
manipulations and plotting
of functions and data and implementation of algorithms |
MathWorks |
1980 |
[65] |
IBM PC |
Personal computer with multiuser support
and multiwindow processing |
Philip Donald Estridge at IBM |
1981 |
[91] |
Xerox 8010 star system |
Personal computer |
Xerox Corporation |
1981 |
[82] |
Assisted Model |
Software to apply force |
Peter Kollman and his |
1981 |
[71, 92, |
Building with |
fields for molecular |
team at University of |
93] |
|
Energy |
dynamics of |
California |
||
Refinement |
biomolecules |
|||
(AMBER) |
||||
CLOGP |
Software used for predicting lipophilicity |
Prof. Al Leo at Pomona College |
1982 |
[74] |
Chemistry at Harvard Macromolecular Mechanics
(CHARMM) |
Software for molecular mechanics
and molecular dynamics
simulation program |
Prof. Martin Karplus at Harvard University |
1983 |
[94] |
Macro Model |
Program for molecular modeling of organic compounds
and biopolymers; force
fields plus energy
minimizing algorithms |
Fariborz Mohamadi and colleagues, Columbia University, New York; Schrödinger, LLC (2000 Onwards) |
1986 |
[78, 95] |
Stata |
Statistical program |
StataCorp |
1985 |
[79] |
Microsoft Paint |
Microsoft paint is a software used as painting and graphics editing |
Microsoft |
1985 |
[96] |
Interesting development |
Application | Developer/team/ organization |
Year |
Ref. |
ChemDraw | Software for chemical structure drawing, representation, NMR, and mass spectrum simulation | David A. Evans and Stewart Rubenstein, and later by CambridgeSoft, and recently by PerkinElmer from 2011 | 1985 | [67, 68] |
X-PLOR | X-PLOR is a software used for protein crystallography | Dr. Axel T. Brunger | 1987 | [97] |
TOPKAT | Correlative SAR system | Kurt Enslein, from | Late | [75–77, |
for predicting preclinical | Health Designs | 1980s | 98] | |
toxicity | (Accelry), and later | |||
acquired by Biovia | ||||
Design-Expert | Software used in statistical data analysis and design of experiments | Stat-Ease, Inc. | 1988 | [80] |
AutoDock | Molecular modeling software | Scripps Research | 1989 | [73] |
Python | Programming language | Guido van Rossum | 1989 | [99] |
PharmApp for developments of 1990s
Interesting development |
Application |
Developer/team/ organization |
Year |
Ref. |
Linux |
Operating system |
Linus Torvalds at the Helsinki University of Technology, Finland; Free Software Foundation (FSF) |
1990s |
[100] |
Integrated Scientific Information System/Draw (ISIS/Draw) |
Software for 2D drawing
of structures and equations; reaction validation features and could calculate formula and molecular weight |
Molecular Design Limited (MDL) |
1991 |
[106] |
Windows NT |
Processor-independent, multiprocessing, and multiuser operating system |
Microsoft |
1993 |
[62] |
JAVA |
Platform-independent programming language |
James Gosling, Patrick Naughton,
Chris Warth, Ed Frank, and
Mike Sheridan at Sun Microsystems |
1995 |
[102] |
R |
Programming language used for statistical computing and data analysis |
Robert Gentleman and Ross Ihaka |
1995 |
[103] |
GastroPlus® |
First commercial PBPK modeling based on advanced compartmental absorption and transit (ACAT)
model |
Simulations Plus |
1998 |
[107] |
PharmApp for developments of 2000s
Interesting development |
Application |
Developer/team/ organization |
Year |
Ref. |
Materials Studio |
Module-based molecular
simulating software |
Accelrys (now
Biovia) |
2000 |
[127] [62] |
Discovery Studio |
Module-based comprehensive
software suite for drug
discovery |
Accelrys (now
Biovia) |
2002 |
[128] |
MOE |
Integrated platform for computer-aided molecular design and drug discovery |
Chemical Computing Group |
Around 2000 |
[138] |
BioSuite |
Modular software for genome/proteome sequencing, 3D modeling,
molecular dynamics simulation, and drug design |
CSIR and TCS |
2004 |
[139] |
Glide |
Virtual screening and molecular
docking |
Schrödinger, Inc. |
2004 |
[129, 130, 140] |
PubChem |
Freely accessible database of chemical molecules
and their biological activity |
National Center for Biotechnology Information |
2004 |
[132] |
ZINC |
Freely accessible database of biologically relevant
and 3D form of the molecule for virtual screening
and docking |
Irwin and Shoichet Labs, University of California |
2004 |
[141] |
Surflex- Dock |
Virtual screening software and
docking |
Tripos Inc.
(Now Certara) |
2006 |
[142] |
DrugBank |
Freely accessible database of drugs, drug targets, and drug actions |
Dr. David Wishart, University of Alberta, and The Metabolomics Innovation Centre, University of Alberta |
2006 |
[143] |
Lead Finder |
Molecular docking |
Mol Tech
Ltd. |
2007 |
[144] |
ChemSpider |
Database |
Royal Society of Chemistry |
2007 |
[132] |
DOCK Blaster |
Connects ZINC databases with
DOCK to ascertain suitable ligand for protein |
University of California |
2009 |
[145] |
Softwares for design of experiments (DOE)
Software, latest
version, and its release date |
Brief description |
URL |
Design-Expert Version 13, January
2021 |
First launch in 1988;
provides 3D plots that can be rotated to visualize response
surfaces; numerical and graphical optimization; and access by subscription |
|
JMP Version
16; March 2021 |
JMP (John’s Macintosh Project) was developed in 1989; Features: control charts, elementary design of experiments (DOE), survival features, graph
builder, dynamic bubble plots, data mining, predictive analytics, and automated model building; orthogonal supersaturated design; and access
by subscription |
|
Minitab 20.2.0; April 2021 |
First launch in 1972;
powerful DOE software
used for automated data analysis, graphic, and help features, including MS-Excel compatibility and almost all designs of RSM; and access by subscription |
|
XLSTAT version 2021.2; April 2021 |
First launch in 1993;
flexible Excel data analysis add-on
software; helps in selection of an experimental design;
DOE for screening, response surface, and mixture designs
and their analysis; and access by subscription |
|
Statistica 14.0; December 2020 |
First launch in Mid-1980s; Statistica provides data analysis, data management, statistics, data mining, machine
learning, text analytics, and data visualization procedures; access by subscription |
|
SPSS Statistics 27; November 2020 |
Comprehensive statistical software with features implementing experimental design |
|
MODDE® 12; February 2017 |
Use for evaluation of fitting
of model and suitable for response surface modeling; access by subscription |
https://www.sartorius.com/en/ products/process-analytical- technology/data-analytics- software/support/knowledge-base/ modde-12-550758 |
Prism 9.1.0 (Graph Pad Software); March 2021 |
First launch in 1989;
used for data analysis, statistics, and graphing |
Software, latest
version, and its release date |
Brief description |
URL |
Statgraphics Centurion
19; 2020 |
First launch in 1980;
Statgraphics provide extensive catalog of screening, response surface, optimal designs, mixture, and RPD experiments; access
by subscription |
Types of computer systems
and their application in pharmaceutical sciences
Advanced computing techniques in pharmaceutical formulations |
Application |
Ref. |
Expert- and knowledge-based systems |
Generation of initial formulations and processing conditions ab initio |
[31] |
Neural computing |
For modeling formulation and process data to explore
relationships within the dataset and optimize the formulation |
[5] |
Computer simulation |
For the development of mathematical models
for the interactions between the ingredients of formulation and the manufacturing process to predict
outcomes |
[32] |
Various pharmacokinetic softwares, their features, latest version, and platform to use
Software; latest version; release date |
Brief description |
Date of release of first version |
URL |
Phoenix; WinNonlin 8.3; June 2020 |
Noncompartmental
analysis (NCA), PK/PD modeling, and toxicokinetic (TK) modeling; runs on Windows |
1990 |
|
GastroPlus® 9.8; Oct. 2020 |
Available as ten different modules, viz. Drug
Drug Interaction, PBPKPlus™,
ADMET Predictor®, Additional Dosage Routes, Metabolism and Transporter, Biologics,
Optimization, PDPlus™,
PKPlus™, and
IVIVCPlus™; PBPK modeling, PBBM modeling, in silico PK prediction, IVIVC prediction, virtual trials, prediction of drug-drug interactions food effects and pharmacodynamics, optimization of generic formulations, and population pharmacokinetic; runs on Windows |
August 1998 |
|
NONMEM® |
Nonlinear
mixed-effect modeling software program (NONMEM®),
Population PK and PK/PD modeling (PREDPP); runs on Windows or Linux; access
by subscription |
1989 |
|
MATLAB Simbiology |
PBPK, PKPD, quantitative systems
pharmacology, model building either MATLAB programming or Simbiology block
diagram editor; noncompartment analysis |
Late 1970 (MATLB) |
|
Simcyp™ PBPK Simulator version 20 |
Physiologically based pharmacokinetic (PBPK) modeling and simulation; models for maternal health, biowaivers, and long-acting injectable drugs; separate modules
for animals, pediatric, cardiac safety, long acting, injectables, and |
1999 |
Software; latest version; release date |
Brief description |
Date of release of first version |
URL |
|
lactation; SimCyp founded in 1999 |
|
|
PK-Sim™ (Part of OSP Suite. Version 9.1; July 2020) |
PK-Sim™ allows PBPK modeling and PBPK/PD modeling;
based on compartmental gastrointestinal (GI) transit
model; communication and exchange of data via Matlab®,
R, and MS Excel; an open access
suite; both PK-Sim™ and modeling software tool MoBi® are integrated into OSP;
run on Windows |
Mid- 1990s |
|
PKBugs version 2; WinBUGS 1.4; 2007 |
Complex population PK/PD modeling;
Markov Chain Monte Carlo methods
to be applied
to PK/PD analysis; no limitation of dimensional array and size;
free to download;
run on Windows |
1997 |
https://www.mrc-bsu.cam.ac. uk/software/bugs/the-bugs- project-winbugs/winbugs- development/ |
MEDICI-PK™ |
Whole-body PK modeling; |
Mid- |
|
virtual PK laboratory based |
2000s |
||
on modules; in silico |
(2005– |
||
comparative PK studies of |
2006) |
||
different species, different |
|||
individuals, different |
|||
compounds, and/or
different |
|||
models; bidirectional |
|||
interface to Microsoft Excel; |
|||
access by subscription |
|||
Kinetica 5.1 2014 |
Noncompartment, compartment, and population PK/PD modeling; bioequivalence, protein, and enzyme kinetics computations; data communication with Thermo Scientific
Watson LIMS™, MS Excel,
Oracle, and others;
access by subscription |
|
Software used in Quality by Design (QbD)
Sr. no. |
Software |
Features |
1. |
Fusion QbD |
Advanced approach toward experimental design and multivariate analysis |
2. |
Master control QbD |
Effective and efficient implementation of principles of QbD |
3. |
Lean QbD |
Knowledge-assisted structured applications that can
perform several tasks related to QbD implementation |
4. |
QbD Vision |
|
5. |
QbD Software |
List of software used for 3D printing
Software |
Function |
Level |
System requirement |
3D Builder |
Design |
Beginner |
Windows |
3D Slash |
Design |
Beginner |
Browser |
3DPrinterOS |
STL Editor |
Beginner |
Windows, Mac, Ubuntu, Raspberry
Pi |
3D-Tool Free Viewer |
STL Analysis |
Intermediate |
Windows |
AstroPrint |
Slicer, 3D Printer Host |
Beginner |
Browser |
Blender |
Design |
Professional |
Windows, Mac, Linux |
FreeCAD |
Design |
Intermediate |
Windows, Mac, Linux |
Fusion 360 |
Design |
Intermediate |
Windows, Mac |
KISSlicer |
Slicer |
Intermediate |
Windows, Mac, Linux |
MakerBot Print |
Slicer, 3D Printer Design |
Beginner |
Windows, Mac, Linux |
MatterControl 2.0 |
Slicer, 3D Printer Host, Design |
Beginner |
Windows, Mac, Linux |
MeshLab |
STL Editor,
STL Repair |
Professional |
Windows, Mac, Linux |
Netfabb |
STL Repair, Slicer |
Professional |
Windows |
OctoPrint |
Slicer, 3D Printer Host |
Intermediate |
Windows, Mac, Linux |
OnShape |
Design |
Professional |
Browser |
OpenSCAD |
Design |
Intermediate |
Windows, Mac, Linux |
PrusaSlicer |
Slicer |
Beginner |
Windows, Mac, Linux |
Repetier-Host |
Slicer, 3D Printer Host |
Intermediate |
Windows, Mac, Linux |
Rhinoceros 3D |
Design |
Beginner |
Windows, Mac, Linux |
SketchUp Free |
Design |
Intermediate |
Browser |
SliceCrafter |
Slicer |
Intermediate |
Browser |
Solidworks |
Design |
Beginner |
Windows, Mac, Linux |
TinkerCAD |
Design |
Beginner |
Browser |
Ultimaker Cura |
Slicer, 3D Printer Host |
Beginner |
Windows, Mac, Linux |
Vectary |
Design |
Intermediate |
Browser |
ZBrushCoreMini |
Design |
Beginner |
Windows, Mac |
List of research findings done on the 3D printed formulations
3D printing technology |
Formulation |
Application |
Materials |
Ref. |
3D printing based on powder layering |
Absorbable device |
Novel controlled releasing drug delivery system |
Polycaprolactone
(PCL) with methylene blue and polyethylene oxide
matrix materials |
[78] |
Tablet dosage form |
Novel delayed drug release
formulation |
Drug and fluorescein disodium
salt, Eudragit, acetone, polyvinylpyrrolidone, and other excipients |
[62] |
|
Implants |
Multi-drug implants for bone tuberculosis |
Isoniazid, rifampicin, and other excipients |
[79] |
|
Bioceramic implants |
Formulation comprising antibiotics |
Vancomycin hydrochloride, tetracycline hydrochloride, and ofloxacin with other excipients |
[80] |
|
Mesoporous biologically active
glass |
Biologically active glass for restoration of bone |
Dexamethasone powder
and polyvinyl alcohol |
[81] |
|
Tablet dosage form |
Rapid disintegrating soft tablets |
Paracetamol and
other excipients |
[65] |
|
Tablet dosage form |
Controlled drug delivery system |
Paracetamol and
other excipients |
[82] |
|
Tablet dosage form |
Featured complex drug-releasing formulation |
Chlorpheniramine
maleate and other excipients |
[67] |
|
Cubical architecture |
Consistent rate drug-releasing formulation |
Pseudoephedrine hydrochloride and related excipients |
[83] |
|
Implantable formulation |
Antibiotic laden implant |
Antibiotic drug and excipients |
[84] |
|
Multiple- layered drug- eluting
device |
A multiple-layered drug-eluting device in the form of a doughnut |
Paracetamol and excipients |
[85] |
|
Orally dispersible formulation |
Quick dispersible dosage form |
Levetiracetam and other excipients |
[86] |
|
Implantable formulation |
The implantable complex design meant for prophylaxis action |
Antibiotic drug and excipients |
[87] |
|
Hydraulic adhesive material |
Restoration of bone structure |
Tricalcium derivative cement and other excipients |
[88] |
3D printing technology |
Formulation |
Application |
Materials |
Ref. |
|
|
using cementing material |
|
|
Selective Laser Sintering 3D printing |
Shell core structure |
Controlled drug- releasing device |
Polyamide |
[89] |
Cubical hollow matrices |
Perforated matrix devices |
Nylon and other
dyes |
[90] |
|
Biopolymeric microstructures |
Drug-eluting polymeric
discs |
PLA |
[91] |
|
Fused Deposition Modelling
technology |
Tablet dosage form |
Controlled drug delivery system
as personalized medicine |
PVA |
[64] |
Tablet dosage form |
Various geometrical- shaped printlets |
Paracetamol |
[92] |
|
Capsule |
Pulsatile drug delivery system |
Paracetamol and
other excipients |
[93] |
|
Tablet dosage form |
Modified release drug delivery form |
PVA |
[94] |
|
Tablet dosage form |
Extended drug- releasing formulation |
Steroid and PVA |
[95] |
|
Tablet dosage form |
Flexi-dose formulation |
Theophylline and Eudragit |
[96] |
|
Discs |
Medical devices |
Nitrofurantoin and excipients |
[97] |
|
Discs |
Drug laden implants |
Nitrofurantoin and excipients |
[98] |
|
Structured matrix reservoir |
Controlled releasing matrices |
Dye and
excipients |
[99] |
|
Medical devices |
Sustained releasing dosage form containing chemotherapeutic drugs |
Chemotherapeutic
drugs and excipients |
[100] |
|
Combinational 3D printing |
Implantable device |
3D printed formulation |
Antibiotic and excipients |
[101] |
List of tools and databases used in computational modeling
S. no. |
Tools |
URL address |
Category |
1. |
PubChem |
Ligand databases |
|
2. |
ChEMBL |
||
3. |
DrugBank |
||
4. |
DrugMatrix |
||
5. |
Binding database |
||
6. |
Protein information resource (PIR) |
Protein databases |
|
7. |
SWISS-PROT |
||
8. |
TrEMBL |
https://www.ebi.ac.uk/training/online/ glossary/uniprotkbtrembl |
|
9. |
GenBank |
||
10. |
RefSeq |
||
11. |
Protein Data Bank (PDB) |
||
12. |
Simcyp™ |
PBPK model- based software |
|
13. |
GastroPlus™ |
||
14. |
PK-Sim™ |
||
15. |
MEDICI-PK™ |
||
16. |
Cloe PK™ |
S. no. |
Isolated organ modeling softwares |
Application |
Reference |
||
1. |
Cellular Potts
modeling and subcellular elemental model (SEM) |
Analyze cell movement, cell-cell interactions, and response to an external chemotactic gradient |
[108] |
||
2. |
xPULM |
An electromechanical respiratory in silico, ex vivo lung
simulator |
[109] |
||
3. |
“Bodylight.js.Simulator” |
A visual editor for
creating in-browser dynamic
applications and visualizations |
[110] |
||
4. |
EXSIMO |
An executable simulation model
combines data and code with
the execution environment to run the
computational analysis in an automated manner using tools from software engineering |
[111] |
||
5. |
DILIsym model |
Quantitative systems toxicology software for modeling drug-induced injury |
[112] |
||
|
Cell modeling software |
Application |
Reference |
||
6. |
cBioPortal |
An interactive open-source platform designed for visualizing and analyzing genomics data and selecting better treatments for
patients |
[113] |
||
7. |
CompuCell3D |
A
multicell computer simulation method for finite- element mechanistic modeling, in silico study
of multicell phenomena
at the tissue
scale based on biologically observed
cell behavior and interactions such
as movement, adhesion, growth, death, mitosis, secretion of chemicals, chemotaxis, etc. |
[90] |
||
8. |
“MITOsym” |
MITOsym includes the primary, essential biochemical pathways associated with hepatocellular respiration and bioenergetics, including mitochondrial oxidative phosphorylation, electron transport chain
activity, mitochondrial membrane potential, and glycolysis |
[93] |
||
9. |
MecaGen |
MecaGen enables the specification and control of complex collective movements in 3D space
through a biologically relevant gene regulatory network and parameter
space exploration |
[92] |
||
10. |
E-CELL simulation model |
A simulator of cellular system |
[106] |
||
List of computational simulation software and their applications
S. no. |
Modeling and simulation software |
Application |
URL |
1. |
Simcyp™ Simcyp Pediatric, Simcyp Cardiac
Safety Simulator (CSS), Simcyp Lactation, PBPK simulator |
Simulates drug-drug interaction, absorption modeling, dosing for special populations, and PK prediction |
|
2. |
GastroPlus® |
Simulates intravenous, oral, oral cavity, ocular, inhalation, dermal, subcutaneous, intramuscular absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamic parameters in humans and animals |
|
3. |
PKPlus™ |
Estimates noncompartmental pharmacokinetic (PK) parameters, along with one-, two-,
and three- compartment PK models from pharmacokinetic studies
(IV and/or oral)
without the need to run full simulations |
https://www. simulation-plus.com/ software/gastroplus/ pk-models/ |
4. |
DDDPlus™ |
Simulates in vitro dissolution for formulation and analytical of active pharmaceutical ingredients (API) and formulation excipients under various experimental conditions in seconds |
|
5. |
PDPlus™ |
To predict the PD effect due to alteration in dose, dosage form, and dosing regimens and determine the action’s kinetics. Multiple PD models (therapeutic and adverse) can be accommodated for each drug record |
https://www. simulation-plus. com//software/ gastroplus/pkpd- modeling/ |
6. |
MembranePlus™ |
A software that determines in vitro permeability, in vivo absorption, and systemic clearance/distribution
with the advanced compartmental absorption and transit
(ACAT™) and PBPK models. It also provides in vitro permeability (human colon adenocarcinoma (Caco-2), parallel artificial membrane permeability assay |
S. no. |
Modeling and simulation software |
Application |
URL |
|
|
(PAMPA), or Madin-Derby canine kidney (MDCK))
for optimization |
|
7. |
DILIsym® and NAFLDsym® |
DILIsym is quantitative systems
toxicology (QST) software
for potential drug- induced liver
injury (DILI) responses
at various development stages |
|
8. |
GROMACS |
The most widely used
open- source free
software codes in chemistry, used
primarily for dynamical
simulations of biomolecules, proteins, lipids, and nucleic acids |
https:www.gromacs. org [133] |
9. |
MODELLER |
A program for automated protein homology modeling |
https://salilab.org/ modeller/ https://www.ncbi. nlm.nih.gov/pmc/ articles/ PMC4186674/ |
10. |
Macromoltek |
A molecular simulations software
for antibody modeling,
side-chain packaging, renumbering, and other web-based computational tools for antibody development |
Commercially available
PBPK platforms along with
their associated links
Software |
Developer/distributor |
Associated links |
Custom physiologically based
pharmacokinetics (PBPK) software
Simcyp Simulator |
Simcyp Ltd |
https://www.certara.com/software- old/physiologically-based- pharmacokinetic-modeling-and- simulation/simcyp-simulator/? |
GastroPlus |
Simulations Plus
Inc. |
|
PK-Sim |
Bayer Technology Services |
|
Cloe Predict |
Cyprotex Ltd |
https://www.cyprotex.com/insilico/ physiological_modelling/cloe-pk/ |
General purpose high-level scientific computing software
Berkeley Madonna |
University of California at Berkeley |
|
MATLAB and Simulink product families |
The MathWorks Inc. |
https://in.mathworks.com/products/ matlab.html?s_tid¼hp_products_ matlab |
MLAB |
Civilized Software Inc. |
|
GNU Octave |
GNU |
|
Ecolego |
AFRY |
|
GNU MCSim |
GNU |
Bio-mathematical modeling
software
ADAPT 5 |
Biomedical Simulations Resource, University of Southern California |
|
ModelMaker |
ModelKinetix |
|
NONMEM |
ICON |
|
STELLA |
Isee systems Inc. |
https://www.iseesystems.com/store/ products/stella-architect.aspx |
WinNonlin |
Pharsight, a Certara company |
https://www.certara.com/pkpd- modeling-and-simulation-2/ phoenix-winnonlin-2/?ap¼PKPD |
SAAM II |
The Epsilon Group |
|
acslX |
The AEgis
Technologies Group Inc. |
|
PhysioLab |
Entelos Inc. |
|
PKQuest |
University of Minnesota |
|
gCOAS |
Process Systems Enterprise |
Software |
Developer/distributor |
Associated links |
COPASI |
Biocomplexity Institute of Virginia Tech, University of Heidelberg, University of Connecticut, UConn Health |
|
Maxsim2 |
Fraunhofer-Chalmers
Research Centre |
|
AIMT7: RVIS |
Health and Safety Laboratory |
http://cefic-lri.org/projects/aimt7- rvis-open-access-pbpk-modelling- platform/ |
ADME WorkBench |
AEgis Technologies |
Summary of clinical trial phases
Phase |
Objective |
Number of participants |
References |
Phase 0: Pre-clinical study |
• Study of safety and
efficacy in laboratory animals • Determine safety, dose range
of drug in experimental laboratory animals |
As per study requirement |
|
Phase I: Clinical pharmacology |
• Determine safety of drug
dose in human • Evaluate therapeutic dose
range • Identify side effects of the treatment |
20–80 |
|
Phase II: Drug efficacy/ safety, dose ranging |
• Determine effectiveness of the treatment • Evaluate safety to all pharmacological parameters |
100–300 |
|
Phase III: Long-term, large scale, confirmatory |
• Evaluate therapeutic effectiveness • Monitoring the side effects • Comparison with available treatments |
1000–5000 |
|
Phase IV:
Post-market monitoring |
• Determine adverse drug reaction after marketing of drug in wide population •
Evaluate long-term safety |
1000+ |
Sr. no. |
Clinical development stages |
Softwares |
Applications |
References |
1 |
Protocol design |
Verified Clinical Trials (VCT), TriNetX |
Analyze protocols |
|
2 |
Patient management |
PatientsLikeMe,
TrialSpark, TrialX, SubjectWell, StudyKIK, Seeker
Health, mProve Health, Langland, Clinical Connection, Comprehend Clinically, and FindMeCure |
Patient recruitment and retention |
|
3 |
Clinical data management |
Electronic data capturing (EDC) like Oracle
Clinical, Medidata Rave and Inform
by Phase Forward
Electronic health records (EHR) |
Capture, store and manage all safety
data |
|
4 |
Study monitoring |
Oracle Clinical, Phase Forward, NetRegulus, Aris Global |
Adverse event reporting |
|
5 |
Regulatory reporting |
SyTech, Wimmer
systems |
Data analysis and reporting, regulatory submission |
Differences among AI, ML, and DL
Artificial intelligence (AI) |
Machine learning (ML) |
Deep learning (DL) |
AI originated around the 1950s |
ML originated around the 1960s |
DL originated around the 1970s |
The study of pattern
recognition and mimicking human behavior by machines can be described as AI |
It is a subset
of AI and can be described as the study
of computer algorithms which improves automatically through experience and by use of data |
It is a subset of ML and AI which is based
on Artificial neural
networks (ANN) to mimic human
brain-like behaviors |
AI focuses on learning, reasoning, and self-correction |
ML focuses on learning through experience without any human intervention |
ML focuses on information processing pattern mechanisms to identify patterns
just like the
human brain |
AI exhibits intelligence through
decision-making |
ML is an AI algorithm which allows systems to learn from data |
In the case of DL, the ANN analyzes the data and provides output |
Efficiency of AI is based
on the efficiency
provided by the ML or DL |
Less efficient as compared to DL and cannot
work properly for a higher
amount of data |
The most efficient and powerful than ML as it can easily work through a large set of data |
Three broad categories of AI are ANI, AGI, and ASI |
Four broad categories are supervised, unsupervised, semi-supervised, and reinforcement learning |
Some deep neural networks are convolutional, recurrent, autoencoder, generative adversarial network, etc. |
Some AI tools used in drug discovery
AI tool |
AI approach |
Application |
Ref |
Hit Dexter |
Randomized trees classifiers (ML approach) |
Prediction of small molecule
for positive response
in biochemical assays.
Available at https:// nerdd.univie.ac.at/ hitdexter/ |
[103, 104] |
HitPick |
B-score method (hit identification) and combination of Laplacian- modified naïve
Bayesian target models
and 1-nearest- neighbor
(1NN) similarity searching
(target prediction) |
Hit identification and target prediction of chemical screening
using ChEMBL bioactivity data. Available at http://mips.helmholtz- muenchen.de/hitpick/cgi- bin/index.cgi? content¼hitIdentification. html |
[105, 106] |
Chemputer |
Modular robotic system equipped
with AI |
Automation of chemical synthesis
and analysis |
[107] |
PotentialNet |
Multistaged spatial
gated graph CNN |
Molecular property prediction like
ADMET, solubility, protein-ligand binding
affinity, etc. |
[108] |
REINVENT |
Open-source Python application; PyTorch as a deep learning engine, and RDKit version as a chemistry
engine |
De novo design of small molecules; publicly available at https://github. com/MolecularAI/Reinvent |
[109] |
AlphaFold |
CNN |
Predicts 3D structure of protein with
high accuracy |
[110] |
DeepTox |
DNNs comprising SVM, RF, and elastic
nets |
Prediction of toxicity of drugs and environmental chemicals |
[111] |
The Polypharmacology Browser
(PPB2) |
Combination of nearest neighbor
searches and naïve Bayes |
Prediction and used as a target prediction tool.
It also computes
ligand similarities. Available at https://ppb2.gdb.tools/ |
[112] |
ORGANIC |
GAN |
Molecular generation tool used to create
molecules with desired properties; inverse design
chemistry |
[113, 114] |
DeepDDI |
DNN |
Prediction of drug–drug interactions (and drug–food constituent interactions) |
[115] |
CASE Ultra |
QSAR and ML |
Prediction of preclinical toxicity
of potential molecules |
[116] |
ADMETlab |
QSAR regression or classification
models using |
|
[117] |
AI tool |
AI approach |
Application |
Ref |
|
six different machine learning
algorithms |
Prediction of ADMET; available
at http://admet. scbdd.com/ |
|
Mol-CycleGAN |
GAN with reinforcement learning |
Molecule design for a desired physicochemical or structural property |
[118] |
Applications of ANN in preformulation studies
AI tool |
Formulation/preformulation characteristics |
Input |
Output |
Outcome of study |
Ref. |
Kohonen’s
SOMs |
Tablets prepared by direct |
Wetting time,
water |
Disintegration |
Classified the disintegration |
[146] |
(ViscoverySOMine software) |
compression; 11 different |
absorption ratio,
particle |
time of tablets |
actions of test disintegrants |
|
disintegrants were
tested for |
size, morphological |
into four
distinct clusters |
|||
disintegration of tablets |
observation, swelling |
||||
property, and relaxation time |
|||||
ANN (CAD/Chem) |
Polymer blends (HPMC, PVP, HPC, carrageenan, sodium alginate) in water for
glass transition temperature |
Matrix polymer
composition |
Glass transition temperatures, viscosity, water uptake |
ANNs accurately predicted outputs with
a low % error (0–8%) of prediction |
[147] |
BT algorithm and multiple regression |
Tablets prepared by direct compression method
for tensile strength |
Particle size distribution, Hausner
ratio, moisture content,
elastic recovery, and molecular weight
of 81 drugs |
Tensile strength |
BT model had high performance |
[148] |
ANN (Matlab 6.1) and regression model |
Solubility of drugs in water– cosolvent mixtures |
Experimental solubility of solutes in water–cosolvent systems (35 datasets) |
Solubility |
ANN was superior to the regression model |
[149] |
ANN |
Hydrotropic solubilization of indomethacin in water |
Experimental data,
together with various known and computed physicochemical properties |
Solubility in water |
In silico screening tool
for drug/hydrotrope systems using ANN |
[150] |
ANN and MLR models |
Skin permeability of new chemical entities |
Skin permeability, Abraham descriptors of R2 (excess molar refraction), the dipolarity/polarizability, the overall
or effective hydrogen-bond acidity and |
Skin permeability |
Better prediction of skin permeability with
ANN |
[151] |
AI tool |
Formulation/preformulation characteristics |
Input |
Output |
Outcome of study |
Ref. |
|
|
basicity, and the McGowan (215 datasets) |
|
|
|
DNN model and LASSO models |
Permeability of small drug- like molecules across lipid membranes |
Molecular descriptors and fingerprints |
Membrane permeability |
DNN model using molecular
fingerprints can help develop a more accurate
mapping |
[152] |
MLP and SVM |
Predicting CNS permeability of drug molecules |
MW, surface area, volume, log P, HLB,
CNS activity (+/ -), H 3d, H donor,
H acceptor |
CNS permeability |
SVM algorithm was superior |
[153] |
ANNs, (BrainMaker Professional) and
KNN |
Pharmaceutical fingerprinting of samples of L-tryptophan (LT) (API) on the basis
of HPLC trace impurity pattern |
899 data entries extracted from each HPLC chromatogram; 253 chromatograms |
Classifier developed |
ANN with 46 inputs
was superior to all other classifiers with 93% accuracy |
[154] |
SVM; four different types
of ANN, namely, backpropagation (BPNN), genetic BPNN Mind Evolutionary Algorithm- Based BPNN (MEA-BPNN), and Extreme Learning Machine
(ELM) |
Powder compactability of powder blends
for tensile strength
and brittleness |
Raw material attribute inputs;
Conc. of material for shell and core (% wt/v), type of material for core, shell |
Tensile strength and brittleness index |
ANN algorithms were more capable of handling convoluted and nonlinear patterns
of dataset |
[155] |
Expert systems
for screening of excipients and formulation designing
Expert system |
Formulation/ dosage form |
Application |
Organization |
Ref. |
CAPEX |
Hard gelatin capsules |
Formulation designing and prediction of dissolution rate |
University of Maryland Baltimore
County |
[171, 172] |
ESFppop |
Push-pull osmotic pump (ppop)
of poorly water-soluble drugs |
Predict composition of push-pull
osmotic tablets and drug release |
Shenyang Pharmaceutical University, China |
[173] |
SeDeM expert system |
Matrix tablets of theophylline |
SeDeM expert system conceived
and applied to assess compressibility of powder mixtures |
University of Barcelona, Spain |
[174] |
SeDeM expert system |
ODTs |
Screening of excipients on the basis
of Index of Good compression (IGC) for preparing
ODTs |
University of Barcelona, Barcelona, Spain |
[175] |
SeDeM- ODT expert system |
ODTs |
New model that provides the Index of Good Compressibility and Bucodispersibility (IGCB index) to assess
fast in vitro
disintegration of ODTs prepared by direct compression |
Novartis Pharmaceutical- Spain and University of Barcelona, Barcelona, Spain |
[176] |
SeDeM expert system |
Drug excipient powder blend |
Assess suitability of theophylline and lactose blends for direct compression |
University of Seville, Spain |
[177] |
SeDeM expert system |
Matrix tablets
of theophylline for sustained release |
Assess suitability of biodegradable polyurethanes and theophylline blends for direct
compression |
University of Seville, Spain |
[178] |
SeDeM expert system |
Medicated chewing gum tablets
of lyophilized lysozyme |
Assess powder blends for its suitability for direct compression |
Goethe-University Frankfurt, Germany |
[179] |
SeDeM and SeDeM- ODT |
Preformulation studies
of pediatric ibuprofen
ODT tablets |
Compressibility and bucodispersibilty of ibuprofen-Ludiflash blends;
optimized ODT tablets |
University of Medicine and Pharmacy Tirgu Mureş, Romania |
[180] |
Applications of ANN in formulation development and optimization
AI tool |
Formulation/dosage form |
Inputs |
Output |
Outcome |
Ref. |
ANN-based expert system (PharmCAD
expert system) |
Ketoprofen solid dispersions (SD)
and physical mixtures |
7 inputs; type and preparation technology as well as qualitative and quantitative composition of SD and
physical mixtures (PM) |
Drug dissolution |
ANNs functioned well as decision support system and data-mining tool |
[184] |
ANN-based expert system (PharmCAD
expert system) |
Solid dispersion |
16 inputs; MW of drug and two carriers, amount
of drug and two carriers, Connectivity Index (CI)
of drug and two carriers, formulation type, preparation technology, cooing conditions, rpm paddle/basket, pH of dissolution media, time of dissolution |
Amount of drug dissolved |
PharmCAD expert system for deriving knowledge
from empirical data |
[185] |
Fuzzy logic-based expert system |
Freeze-dried peptide and protein-based formulations |
Off coloring, image entropy, cake collapse, and light saturation were inputs |
Quality of cake (quality attributes collapse, glassiness, uniformity, and color) |
High-throughput formulation screening by image analysis |
[186] |
ANN and DNN model |
ODTs |
Molecular parameters of drug, amount of drugs, amount
of excipients, type of encoded
excipients, manufacturing parameters, and disintegration time |
Disintegration time |
DNN performs well in all three datasets with over 80% accuracy |
[187] |
DNN, MLR, PLSR, SVM, ANNs, RF,
k-NN |
|
Molecular parameters of drug, amount of drugs, |
|
|
[89] |
AI tool |
Formulation/dosage form |
Inputs |
Output |
Outcome |
Ref. |
|
Oral sustained release matrix tablets
and fast disintegrating films |
amount of excipients, type of encoded
excipients, manufacturing parameters, and disintegration time |
In vitro
characteristics; disintegration and drug release |
DNN model as superior to other machine learning models |
|
ANN model |
Topical matrix patches of diclofenac sodium |
Time, chitosan amount, and carrageenan amount |
Drug release and the ex vitro skin permeation kinetics |
• ANN-predicted outputs
with reasonable accuracy |
[188] |
• INForm V.4 ANN for neural networks, FormRules V.3.32 for neurofuzzy logic,
and INForm V.4 GEP |
Ramipril tablets prepared by the direct
compression |
HPMC, lubricant type, lubricant
concentration |
Tablet weight, friability, disintegration time, dissolution |
Support decision-making processes; optimized formulation was within the design space |
[189] |
MLP (ANN Neural
Power® version 3.1) |
Mesalamine matrix tablets by wet compression |
9 inputs; amount of excipients |
Friability, thickness, hardness, weight variation, content uniformity, dissolution |
ANN-aided optimized formulation |
[190] |
MLP and Box Behnken
Design |
Multiple-unit prednisone pellet system |
MCC concentration, SSG concentration, spheronization time and extrusion speed |
Aspect ratio, drug release at different time
points, yield |
ANN was recommended as complement RSM for optimization (Box Behnken design) |
[191] |
Supervised MLP (STATISTICA 7.0
Neural Networks and MATLAB R2014b)
and D-Optimal mixture
design |
Cross-linked polymeric ibuprofen printlets by digital light
processing (DLP) |
Amount of PEGDA, PEG 400, and
water |
In vitro drug release at different time points |
Both ANNs performed better than D-optimal mixture design |
[192] |
A generalized regression neural network (GRNN) (TIBCO Statistica® Software),
and self- |
DLP-based 3D-printed tablets of atomoxetine |
Data from
23 experiments; input variables were:
tablet thickness and
drug loading |
Release rate
after 15, 30, 60, 120,
240, and 360 min |
ANN predictive models for atomoxetine release rate developed |
[193] |
AI tool |
Formulation/dosage form |
Inputs |
Output |
Outcome |
Ref. |
|
|
|
Kawatika’s fitting parameters (a, 1/b) minitablets’ avg. weight,
weight variation, and relative density |
|
|
FDA-approved AI/ML-based devices
Medicinal field |
Devices (company, date of approval) |
Cardiology |
Imbio RV/LV
Software (Imbio, LLC,
2021) Caption Interpretation Automated Ejection Fraction Software (Caption Health, 2020) Eko Analysis Software (Eko Devices, Inc.,
2020) AI-ECG Platform (Shenzhen Carewell Electronics Ltd., 2019) EchoGo Core
(Ultromics Ltd., 2019) Arterys Cardio DL (ARTERYS, Inc., 2018) EchoMD
(Bay Labs, Inc.,
2018) |
Endocrinology |
Guardian Connect System (Medtronic MiniMed, Inc., 2018) DreaMed Advisor Pro (DreaMed Diabetes Ltd., 2018) |
Radiology |
MEDO-Thyroid (Medo.AI, 2021) LVivo Software Application (DiA Imaging
Analysis Ltd., 2020) FastStroke, CT Perfusion 4D (GE Medical
Systems SCS, 2020) TransparaTM (Screenpoint Medical B.V, 2019) Deep Learning Image Reconstruction (GE Medical Systems, LL, 2019) HealthPNX
(Zebra Medical Vision
Ltd., 2019) Advanced Intelligent Clear-IQ Engine
(AiCE) (Canon Medical
Systems Corporation, 2019) SubtleMR (Subtle Medical, Inc., 2019) AI-Rad Companion (Pulmonary) (Siemens Medical Solutions USA,
Inc., 2019) EchoMD Automated Ejection Fraction Software (Bay Labs
Inc., 2018) SubtlePET
(Subtle Medical, Inc.,
2018) |
Neurology |
Viz ICH (Viz. AI, inc., 2020) Accipiolx (MaxQ AI Ltd.,
2018) Icobrain (Icometrix,2018) ContaCT
(Viz.AI, 2018) EnsoSleep
(EnsoData, Inc., 2017) |
Internal medicine |
FerriSmart Analysis System (Resonance Health Analysis Services Pty Ltd, 2018) |
Ophthalmology |
IDx-DR (Digital Diagnostics, 2018) |
Emergency Medicine |
Critical Care Suite (GE Medical Systems, LLC., 2019) HelathPNX
(Zebra Medical Vision
Ltd., 2019) BriefCase
(Aidoc Medical, Ltd.,
July 2018) OsteoDetect (ImagenTechnologies, Inc., 2018) |
Oncology |
QuantX (Quantitative Insights, Inc.,
2020) Transpara™ (ScreenPoint Medical
B.V., 2019) cmTriage (CureMetrix, Inc., 2019) ArterysMICA (Arterys, Inc., 2018) Arterys Oncology DL (Arterys Inc.,
2018) Profound™ AI Software V 2.1 (CAD,
Inc, 2018) |
AI company |
AI platform |
Major collaboration with pharmaceutical company |
Date of collaboration |
Use |
Ref. |
Exscientia |
Centaur Chemist |
Bayer |
January 2020 |
Identify and optimize novel lead molecule for oncological and cardiovascular disease |
[237] |
Sanofi |
May 2017 |
To find bispecific small molecules for diabetes and comorbidities |
|||
GSK |
April 2019 |
Finding novel drug molecules
for targeting pathways of chronic obstructive pulmonary disorders |
|||
Atomwise |
AtomNet |
Lilly |
June 2019 |
To develop drugs on novel protein
targets |
[238] |
Cyclia |
MatchMaker |
Bayer |
November 2018 |
Pharmacokinetic property
prediction and multitargeted drug design |
[239] |
Merck |
December 2018 |
Elucidate mechanism of action,
safety profiles of investigational small molecules |
|||
Schrodinger |
|
Bayer |
January 2020 |
Codevelop de novo design
technology to accelerate drug discovery |
[240] |
AstraZeneca |
September 2019 |
To develop advanced computing
technology for drug discovery. |
|||
Insilico Medicine |
Pharma.AI |
GSK |
August, 2017 |
To identify novel biological pathways |
[241] |
Iktos |
Makya™ |
Pfizer |
March 2021 |
De novo designing software
for |
[242] |
AI company |
AI platform |
Major collaboration with pharmaceutical company |
Date of collaboration |
Use |
Ref. |
|
|
|
|
multiparametric optimization |
|
Biovista |
COSS™ |
Astellas |
December 2015 |
Identifying new indications for a number
of undisclosed compounds |
[243] |
Numerate |
Algorithm- driven drug discovery
platform |
Takeda |
June 2017 |
Drug discovery for oncology,
gastroenterology, and CNS
disorders |
[244] |
Berg |
bAlcis® |
AstraZeneca |
August 2017 |
Evaluation of novel targets for neurodegenerative disorders |
[245] |
Sanofi |
October 2017 |
Assess potential biomarkers for seasonal flu vaccine performance |
|||
Benevolent |
Benevolent Platform® |
AstraZeneca |
April 2019 |
NN-based platform for treatment of chronic kidney
disease and idiopathic pulmonary fibrosis |
[246] |
Janssen |
November 2016 |
License the rights to develop and manufacture clinical
stage drug candidates |
Bên NCT có cung cấp các phần mềm này. Liên hệ để biết thêm chi tiết
[/tintuc]